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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading 
cause of cancer-associated death in Western populations. Mor-
phologically, PDAC is characterized by the presence of pancreatic 
intraepithelial neoplasia (PanIN) with an activating KRAS mutation 
occurring in 30% of precursor lesions and in 100% of advanced 
PDAC lesions. Mouse models with pancreas-specific activation of 
oncogenic Kras recapitulate the features of human PDAC.
As a ubiquitously expressed transcription factor, NF-κB can 
regulate the growth and malignancy of many solid tumors, includ-
ing pancreatic cancer, via the regulation of expression of proin-
flammatory and prosurvival genes. However, despite extensive 
characterization of NF-κB signaling, the specific functional roles 
of different members of the NF-κB family in tumor development 
are not completely understood. Recently, the role of the kinase 
IKK2 in PDAC has been explored, demonstrating that IKK exerts 
its tumor-promoting effects through cross-talk with either Notch1 
or p62 protein (1–3). NF-κB inhibition in lung epithelial cells by 
genetic deletion of the NF-κB subunit RelA or IKK2 reduced lung 
tumorigenesis in a Kras-induced mouse model of lung adeno-
carcinoma (4, 5). In keeping with those reports, overexpression 
of IκBα super-repressor (IκBαSR) also resulted in a significantly 
diminished lung tumor growth, supporting a protumorigenic role 
of NF-κB in epithelial cells (6). Although a number of reports dis-
play a tumor-promoting role of NF-κB signaling, it has also been 
reported to exhibit tumor-suppressing functions in different 
tumor models. Hepatocyte-specific knockout of IKKβ resulted 
in increased tumor development in a chemical-driven model of 
hepatic carcinogenesis (7). Another study of hepatic carcinogen-
esis showed that NEMO/IKKγ-mediated NF-κB activation in 
hepatocytes prevented the spontaneous development of hepatic 
steatosis and hepatocellular carcinoma (8, 9), suggesting that 
components of the NF-κB pathway play highly pleiotropic roles 
(10). NF-κB signaling, when activated, can act as both a tumor 
promoter and a tumor suppressor. However, the pathogenetic 
mechanisms by which NF-κB induces these opposite effects dur-
ing tumor development remains unclear.
One possibility is the involvement of NF-κB in the regula-
tion of factors, including CXCL chemokines, IL-6, GM-CSF, and 
MCP-1, -2, and -3, that are subsumed under the term “senescence-
associated secretory phenotype” (SASP) (11). It is now clear that 
SASP components actively participate in the cellular senescence 
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Results
Inactivation of RelA increases pancreatic cancer incidence and 
decreases survival in Kras mice, although tumor proliferation is 
reduced. Although nuclear RelA is typically detectable in human 
pancreatic cancer, its functional relevance for this disease is 
unknown. To determine the function of RelA in pancreatic car-
cinogenesis, we used the LSL-KrasG12D Ptf1a-Creex1 (hereafter 
referred to as Kras) mouse model of pancreatic cancer. Nuclear 
RelA and phosphorylated IκBα were detectable in Kras mice 
starting in preneoplastic lesions and adjacent acinar cells and 
remained visible in established PDAC lesions (Figure 1A). To 
elucidate the role of canonical NF-κB signaling in the Kras mod-
el, we deleted Rela using a conditional Rela allele (LSL-KrasG12D 
Relafl/fl Ptf1a-Creex1 mice, hereafter referred to as Kras RelA) (19). 
Inactivation of RelA in the pancreas had no impact on Ras activ-
ity, while less expression of the target gene IκBα was detectable 
(Figure 1, B and C, and Supplemental Figure 1, A and B; supple-
process. Oncogene-induced senescence (OIS) has only recently 
been shown to govern the carcinogenesis of PDAC (12–16). More 
specifically, OIS in oncogenic KrasG12D mice establishes an incom-
plete tumor-suppressive program that prevents the expansion of 
cells that harbor mutant Kras (17, 18). Despite the potential signifi-
cance of SASP in senescence, little is known about its regulation. 
Importantly, the impact of SASP on pancreatic carcinogenesis has 
not been examined directly.
In this study, we aimed to determine the function of RelA 
in pancreatic cancer in vivo. Surprisingly, our results show that, 
unlike IKK2 or NEMO, RelA has a tumor-suppressive role. RelA 
controls the development of pancreatic cancer, because of its 
function in mediating OIS and immune surveillance. The tumor-
promoting functions of RelA are unmasked upon disabling OIS, 
thus revealing a dual stage function of RelA in the carcinogenesis 
of PDAC. These findings might prove to be of relevance for future 
clinical applications.
Figure 1. RelA deficiency promotes pancreatic carcinogenesis. (A) IHC analysis of RelA and phosphorylated IκBα (pIκBα) in pancreata from Kras mice. 
Representative images show that RelA and pIκBα expression is intense in ductal lesions (black arrowhead), acinar cells (white arrowhead), and PDAC 
lesions from Kras mice. Scale bars: 20 μm. (B) Immunoblot analysis of RelA, truncated RelA (ΔRelA), and IκBα in lysates from 4-week-old Kras and Kras 
RelA mice. β-Actin was used as the loading control. (C) Immunoprecipitation of activated Ras (Ras-RBD) in pancreata from mice with the indicated geno-
types. Lysate from a WT (LSL-KrasG12D) mouse served as the negative control. (D) RelA deficiency cooperates with oncogenic KrasG12D to influence survival. 
Kaplan-Meier analysis shows a median survival of 378 days in Kras RelA mice (n = 33; black line) versus 459 days in Kras mice (n = 28; red line). P < 0.0001 
by Mantel-Cox log rank test; n, number of mice. (E) Tumor incidence was significantly lower in Kras (53.6%) than in Kras RelA (87.9%) cohorts. **P = 0.0041 
by Fisher’s exact test. (F) Proliferation index of pancreatic tumors from mice with the indicated genotypes. The number of BrdU-positive cells was counted 
in 10 fields per mouse. Mean ± SD; n = 3; *P < 0.05 by unpaired t test; n, number of mice. (G) Immunoblot analysis of nuclear extracts from Kras and Kras 
RelA primary pancreatic cancer cell lines displays nuclear RelA in tumor cells isolated from Kras but not RelA-deficient Kras mice. MIA-PACA-2 cell line 
extract served as the positive control. β-Actin and lamin A/C served as loading controls.
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the cohorts (Supplemental Figure 1, C–E). Surprisingly, prolifera-
tion of tumors in established PDAC was 77% lower in Kras mice 
lacking RelA in the pancreas (Figure 1F and Supplemental Figure 
1F). Notably, the deletion of Rela exons 7–10 is maintained in Kras 
RelA primary tumors and metastases, as tumor-derived cell lines 
displayed truncated RelA and therefore lacked nuclear RelA. 
On the other hand, RelA-proficient murine and human pancre-
atic cell lines displayed RelA in the nuclear fraction, suggestive of 
canonical NF-κB activation (Figure 1G and Supplemental Figure 
1G). Moreover, isolated tumor cell lines from Kras RelA mice pro-
liferate significantly less than tumor cells derived from Kras mice 
mental material available online with this article; doi:10.1172/
JCI86477DS1). Cohorts of Kras and Kras RelA mice were moni-
tored for survival. Unexpectedly, overall survival of analyzed Kras 
RelA mice was significantly shorter than that of Kras mice (Fig-
ure 1D). Kras RelA mice reached terminal morbidity between 117 
and 484 days and had a median survival of 378 days (P < 0.0001 
for Kras RelA compared with Kras). In addition, Kras RelA mice 
developed PDAC significantly earlier (350 days in Kras RelA vs. 
443 days in Kras cohort) and showed 1.6-fold increased tumor 
incidence compared to Kras mice (Figure 1E). Tumor type (i.e., 
ductal vs. mixed) and rate of metastasis did not differ between 
Figure 2. Ablation of RelA accelerates progression of mPanIN lesions. (A) Representative macroscopic appearance of pancreata from 13-week-old Kras 
and Kras RelA mice. (B) Pancreas–to–body weight ratio in 13-week-old Kras (n = 15) and Kras RelA (n = 12) mice. Mean ± SEM; **P = 0.0015 by unpaired t 
test; n, number of mice. (C) Number of mPanIN lesions in 13-week-old Kras (n = 3) and Kras RelA (n = 3) mice was counted per ×200 optical field (high-
power field, HPF). Mean ± SD; *P < 0.05, **P < 0.005 by unpaired t test; n, number of mice; N.D., none detectable. (D) Representative H&E staining and 
expression of CK19 and Muc5AC in pancreata from 18-week-old Kras and Kras RelA mice. Positive immunostaining for cytokeratin-19 confirms the ductal 
phenotype of mPanIN lesions. Muc5AC staining can be seen in low-grade lesions (LG mPanIN) but not in high-grade lesions (HG mPanIN) or small PDACs. 
Scale bars: 200 μm and 50 μm.
Downloaded from http://www.jci.org on October 19, 2016.   https://doi.org/10.1172/JCI86477
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 9 2 2 jci.org   Volume 126   Number 8   August 2016
likely that RelA affects mPanIN initiation and progression. There-
fore, we evaluated pancreatic carcinogenesis in RelA-deficient 
Kras mice in more detail. Macroscopically, pancreata of 13-week-
old Kras RelA mice appeared enlarged, indurated, and fibrotic 
when compared with age-matched pancreata of Kras mice (Figure 
2, A and B). Histologically, mPanIN progression in Kras RelA mice 
was significantly accelerated. Indeed, mPanIN-2 and mPanIN-3 
lesions were present in Kras RelA mice as early as 13 weeks of age 
(Figure 2C). IHC examination of Kras RelA pancreata at 18 weeks 
of age revealed clusters of high-grade mPanIN lesions alongside 
small PDACs (Figure 2D). At these time points neither high-grade 
mPanIN lesions nor focal cancers could be detected in Kras mice 
(Figure 2D). In addition, pathways that are known to be relevant for 
ADM formation and mPanIN progression were upregulated in Kras 
(Supplemental Figure 1H). These results indicate that functional 
inactivation of RelA accelerates pancreatic cancer development, 
although proliferation of RelA-deficient tumor cells in estab-
lished PDAC was significantly reduced.
Taken together, our data suggest an opposite function of 
RelA compared with IKK2 and NEMO in pancreatic carcino-
genesis. RelA seems to play a dual stage-dependent role during 
tumor development.
Functional inactivation of RelA accelerates progression of murine 
PanIN (mPanIN) lesions. PDAC is preceded by the evolution of 
PanIN precursor lesions. Under certain conditions, acinar-to-ductal 
metaplasia (ADM) might be critical for the development of PanIN 
lesions. Because functional inactivation of RelA increased tumor 
incidence while reducing tumor cell proliferation, it seemed very 
Figure 3. Transcriptomic analysis of Kras RelA pancreata reveals increased cell differentiation and cell stress signaling. (A, top) Classification of upregu-
lated gene sets (NES ≥1.2; nominal P value < 0.05) in pancreata from Kras and Kras RelA mice, based on KEGG and the transcription factor pathway analy-
ses. (A, bottom and boxed) GSEA illustrating enriched gene sets. KEGG analyses illustrating highly enriched gene sets for “chemokine signaling pathways” 
and “cytokine–cytokine receptor interaction pathways.” (B) Immunofluorescent staining of RelA in Kras and Kras RelA mice. White stars indicate ductal 
lesions, white arrowheads indicate acinar cells. Scale bars: 20 μm. IHC detection of HNF-1β, SOX9, and γ-H2AX in Kras and Kras RelA mice. Scale bars:  
50 μm. 2′,7′-Dichlorofluorescein diacetate (DCFDA) staining. Scale bars: 50 μm. All representative images are shown.
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nisms that promote pancreatic carcinogenesis in Kras RelA mice, we 
performed microarray analysis with RNA from RelA-proficient and 
-deficient Kras total pancreata. In order to ensure homogeneous 
sampling, we used mice younger than 4 weeks of age, as pancreata 
in both groups did not reveal relevant morphological differences at 
this time point (Supplemental Figure 3A). For all the transcriptional 
analysis we compared Kras RelA to Kras pancreas or vice versa. Thus 
the control for Kras RelA was Kras pancreas with RelA proficiency.
RelA mPanIN lesions. These pathways included phosphorylation of 
ERK1/2, STAT3, and c-Jun (Supplemental Figure 2).
These data reveal that inactivation of RelA in Kras mice accel-
erates pancreatic carcinogenesis. Classical NF-κB/RelA signaling 
seems to inhibit ADM and progression of mPanIN lesions, exerting 
a specific tumor suppressor function in pancreatic carcinogenesis.
Loss of functional RelA abrogates NF-κB signatures, but increases 
signatures of cell stress and ADM. To further elucidate the mecha-
Figure 4. RelA deficiency compromises OIS. (A) Ratio of SA-β-Gal–positive mPanIN cells to 
the total number of mPanIN cells in low-grade mPanIN (LG mPanIN) in Kras (6 mice) and Kras 
RelA (5 mice) was counted per ×200 optical field (high-power field, HPF). Mean ± SD;  
n ≥ 50; ***P < 0.0001 by Mann-Whitney test; n, number of HPFs. (B) Detection of senescence 
in pancreatic cryosections from Kras and Kras RelA mice using SA-β-Gal as a marker. Scale 
bars: 20 μm. Representative images are shown. (C) Real-time PCR expression analysis of 
indicated genes in pancreatic lysates from Kras (n = 3) and Kras RelA (n = 3) mice. Error bars 
are shown as SD. Results are the average of 3 independent experiments and are presented 
as mean ± SD; *P < 0.05, **P < 0.005 by unpaired t test; n, number of mice. (D) Pancreatic 
extracts were collected from Kras and Kras RelA genotypes and analyzed by immunoblot 
analysis using antibodies against DCR2, p53, p16, or p19. β-Actin served as loading control. 
(E) Immunohistological analysis for DCR2, p53, p21, or p19 in Kras (n = 3) and Kras RelA (n = 3) 
pancreata. Scale bars: 20 μm. Insets denote single-positive cells. Representative images are 
shown. Quantification of DCR2, p53, p21, and p19 positivity in PanIN cells shown at the bot-
tom. Results are presented as mean ± SD; *P < 0.05, **P < 0.005, ***P < 0.0005 by unpaired 
t test; n, number of mice. (F) SASP gene set enrichment analysis of pancreatic RNA from Kras 
(n = 2) and Kras RelA (n = 2) mice. n, number of mice.
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Figure 5. Regulation of OIS by RelA is mediated by CXCL1. (A) Kras PDECs treated with vehicle control (DMSO) or an NF-κB inhibitor (JSH-23) were plated 
for the senescence assay. Scale bars: 100 μm. Representative images are shown. (B) Conditioned media were collected from PDECs treated with DMSO or 
JSH-23 for cytokine array analysis. The boxed regions on the representative blot indicate the differentially secreted cytokines. (C) Quantitative analysis 
of B, representing the average of the pixel intensity of 2 independent experiments. Mean ± SD; *P < 0.05, **P < 0.005, ***P < 0.0005 by unpaired t test. 
(D) Quantification of SA-β-Gal staining in Kras PDECs treated with DMSO or 100 ng/ml CXCL1. Ratio of SA-β-Gal–positive Kras PDEC cultures to the total 
number of Kras PDECs was counted per ×100 optical high-power field (HPF). Mean ± SD; ***P < 0.0005 by unpaired t test. (E) Representative photomicro-
graphs showing in situ Cxcl1 mRNA in ductal lesions (black arrowhead), in acinar cells (white arrowhead), and in immune cells (black arrow). Scale bars: 50 
μm. (F) Representative SA-β-Gal staining. Scale bars: 100 μm. (G) Ratio of SA-β-Gal–positive cells to the total number of mPanIN cells in 18-week-old Kras 
RelA (5 mice) and Kras RelA IL-8tg (4 mice) was counted per ×200 optical field (HPF). Mean ± SD; n ≥ 28; ***P < 0.0001 by Mann-Whitney test; n, number 
of HPF. (H) Representative H&E staining. Scale bars: 100 μm. (I) Numbers of mPanINs were counted per ×200 optical HPF. Mean ± SD; n ≥ 3; *P < 0.05 by 
unpaired t test; N.D., not detectable; n, number of mice. (J) Representative immunohistological analysis for p53 and 2′,7′-dichlorofluorescein diacetate 
(DCFDA) from Kras RelA (n = 3) and Kras RelA IL-8tg (n = 3) mice. Scale bars: 50 μm. Quantification of p53 positivity shown at the right. Mean ± SD;  
*P < 0.05 by unpaired t test; n, number of mice.
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A total of 390 gene sets were shown to be upregulated, 35 
of which were significantly induced in Kras RelA compared 
with Kras pancreata (Supplemental Figure 3B; gene set enrich-
ment analysis). Furthermore, NF-κB–mediated transcriptional 
pathways were highly enriched in Kras but not in Kras RelA pan-
creata (12% in Kras vs. none in Kras RelA) (Figure 3A). Similarly, 
immunofluorescence staining revealed nuclear RelA in early 
mPanIN lesions and a few adjacent acinar cells of 4-week-old 
Kras mice, while Kras RelA pancreata were negative for nuclear 
RelA (Figure 3B). Moreover, “chemokine signaling pathways” 
(normalized enrichment score[NES] 1.5; P = 0.002) and “cyto-
kine–cytokine receptor interaction pathways” (NES = 1.74; P < 
0.001) were highly enriched in Kras but not in Kras RelA pancre-
ata (Figure 3A). The largest group of upregulated transcription 
factor signatures in Kras mice was associated with proliferation, 
while signatures belonging to cell differentiation were highest 
in the Kras RelA group (Figure 3A). Positive gene set enrichment 
analysis (GSEA) signatures of HNF1_C (NES = 1.39; P = 0.019) 
and SOX9_B1 (NES = 1.48; P = 0.003) in Kras RelA mice indi-
cate the possibility for increased ADM formation (Figure 3A). 
Furthermore, cell stress–associated transcription factor signa-
tures were significantly increased upon loss of functional RelA 
Figure 6. Reinforcement of OIS depends on CXCL1/CXCR2 axis. (A) Representative immunohistological staining for CXCR2 in mPanIN lesions from Kras 
pancreatic tissue and in normal ductal epithelium (inset). Scale bar: 20 μm. (B) Kras PDECs treated with vehicle control (DMSO), CXCL1, or a combination of 
CXCL1 and a CXCR2 inhibitor (SB225002) were plated for the senescence assay. Scale bar: 100 μm. (C) Injection protocol: Each injection contained 0.5 mg 
CXCR2 inhibitor (SB225002) per kilogram body weight. Mice were treated 2 times a week over 4 weeks. One injection was administrated at each injection 
day. Animals were euthanized and dissected 4 days after the last injection. (D) Detection of senescence in pancreatic cryosections from 9-week-old Kras 
mice treated with PBS as vehicle or CXCR2 inhibitor (SB225002), using SA-β-Gal as a marker. Scale bar: 50 μm. Ratio of SA-β-Gal–positive mPanIN cells to 
the total number of mPanIN cells in low-grade mPanIN (LG mPanIN) in 9-week-old Kras mice treated with PBS as vehicle or CXCR2 inhibitor (SB225002) 
was counted per ×200 optical high-power field (HPF). Mean ± SEM; n ≥ 4; *P < 0.05 by Mann-Whitney test; n, number of mice. (E) Representative H&E 
staining of pancreata from 9-week-old Kras mice after treatment with SB225002 or PBS. Scale bar: 50 μm. Number of low-grade (LG) or high-grade (HG) 
mPanIN in 9-week-old Kras mice treated with SB225002 or PBS per ×200 optical field. Mean ± SD; n ≥ 4; *P < 0.05, **P < 0.005 by unpaired t test; n, num-
ber of mice. (F) Representative H&E staining of pancreata from 18-week-old *Kras and *Kras CXCR2null mice. Scale bars: 500 μm, 100 μm. (G) Numbers of 
low-grade (LG) and high-grade (HG) mPanIN in 18-week-old *Kras (n = 2) and *Kras Cxcr2null (n = 3) mice were counted per ×200 optical field (HPF). Mean 
± SD; *P < 0.05 by unpaired t test; N.D., not detectable; n, number of mice.
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Encyclopedia of Genes and Genomes (KEGG) and transcription 
factor signature analysis (Supplemental Table 1, A and B) (1).
Cell stress of acinar cells, for example due to inflamma-
tion, is known to drive ADM. To analyze RelA involvement in 
ADM, we used an in vitro model for exocrine metaplastic con-
version. Acinar pancreatic epithelial explants cultured in a col-
lagen matrix differentiate to duct-like structures after recombi-
nant human TGFα (TGFα ) stimulation, simulating in vivo ADM 
(Figure 3A). Indeed, IHC confirmed pronounced expression of 
SOX9, HNF1β, and γ-H2AX and accumulation of ROS, which are 
indicative of cell differentiation and cell stress, respectively, in 
Kras RelA mice (Figure 3B and Supplemental Figure 3C). These 
effects seem to be RelA-dependent, as deletion of the superordi-
nated kinase IKK2 in Kras mice led to significant upregulation of 
numerous differential gene signatures involved in myc signaling, 
metabolism, biosynthesis, cell stress, and cell cycle using Kyoto 
Figure 7. Pancreas-specific inactivation of CXCR2 is sufficient to bypass OIS. (A) H&E staining, expression of Ki-67, and SA-β-Gal activity in pancreata from 
18-week-old *Kras and *Kras Cxcr2 mice. Scale bars: 500 μm, 100 μm. Representative images are shown. (B) Kaplan-Meier curves documenting a median 
survival of 195 days in *Kras Cxcr2 mice (n = 7; green line) and of 162 days in *Kras CXCR2null mice (n = 40; blue line) versus 291 days in *Kras mice (n = 18; 
magenta line); P = 0.0488 and P = 0.0011 by Mantel-Cox log rank test. n, number of mice. (C) IHC analysis of human pancreatic cancer and tumor-adjacent tis-
sue illustrates positive staining for CXCR2 in low-grade hPanIN (asterisk) and weak staining in high-grade hPanIN (circle) lesions. Scale bars: 20 μm. Represen-
tative images are shown. (D) Real-time PCR expression analysis of mRNA from microdissected human (h) low-grade (LG) PanIN cells and tumor ductal cells 
(hPDAC) for Cxcl1, Cxcl2, Cxcl5, Cxcl6, Cxcl8, and Ccl3. Mean ± SD; n ≥ 11; *P < 0.05, **P < 0.005, ***P < 0.0005 by Mann-Whitney test; n, number of samples.
Downloaded from http://www.jci.org on October 19, 2016.   https://doi.org/10.1172/JCI86477
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 9 2 7jci.org   Volume 126   Number 8   August 2016
Kras RelA acinar explants. In contrast, only 30.26% ± 0.09% of 
acinar explants derived from Kras pancreata transdifferentiated 
to duct-like structures (Supplemental Figure 4E).
These results are consistent with a central role of RelA in con-
trolling NF-κB–mediated gene transcription. In the context of onco-
genic Kras, RelA regulates cell stress and ADM-related pathways.
OIS in early mPanIN lesions in vivo depends on intact RelA func-
tion. Thus far, our data show that inactivation of RelA increases 
cell stress and facilitates mPanIN formation. However, how RelA 
mediates progression of mPanIN lesions to pancreatic cancer 
remained to be explored. Activation of the Kras oncogene can 
mobilize tumor suppressor networks to avert the hazard of malig-
nant transformation. OIS represents such a network, blocking cell 
proliferation almost irreversibly, serving as a vital mechanism 
that protects against cancer. In pancreatic cancer, OIS is induced 
in early mPanIN, thereby impeding progression of preneoplas-
tic lesions to PDAC (14). To identify senescent cells in situ, we 
(Supplemental Figure 4A). Freshly harvested explants from 
pancreata of Relafl/fl (hereafter referred to as RelAwt) and RelAfl/fl 
Ptf1a-Creex1 (hereafter referred to as RelAΔ) littermates consisted 
of acinar cell clusters expressing α-amylase, but not the duct cell 
marker CK8/18 (Supplemental Figure 4B). Treated with 50 ng/
ml TGFα for 5 days, 40.9% ± 3.7% of the RelAΔ acinar explants 
displayed a duct-like morphology characterized by cystic struc-
tures lined with epithelial cells expressing the duct cell marker 
CK19. In contrast, only 24.2% ± 7.2% of acinar explants from 
RelAwt pancreata transdifferentiated to duct-like structures upon 
TGFα treatment (Supplemental Figure 4, A, C, and D). To ana-
lyze ductal conversion in RelAwt versus RelAΔ acinar cells in an 
oncogenic Kras background, we isolated acinar cells from Kras 
and Kras RelA pancreata at an early time point to obtain maxi-
mal amount of exocrine tissue. These acinar cells were planted 
on collagen gel and were treated with 50 ng/ml TGFα for 5 days. 
A duct-like morphology was observed in 59.02% ± 0.14% of the 
Figure 8. Abrogation of OIS in vivo 
illustrates dual role of RelA. (A) 
Kaplan-Meier curves documenting 
a median survival of 82 days in Kras 
RelA Trp53 mice (n = 18; blue line) 
versus 61.5 days in Kras Trp53 mice 
(n = 26; red line). P < 0.0001 by Man-
tel-Cox log rank test; n, number of 
mice. BrdU staining of PDAC tissue 
samples from Kras Trp53 and Kras 
RelA Trp53 mice. Scale bar: 100 μm. 
The number of BrdU-positive cells 
was counted per tumor area. Mean ± 
SD; n = 4; *P = 0.0266 by unpaired t 
test; n, number of mice. (B) Kaplan-
Meier analysis shows a median 
survival of 70 days in Kras RelA p16 
mice (n = 26; orange line) versus 61 
days in Kras p16 mice (n = 19; green 
line); P = 0.0024 by Mantel-Cox log 
rank test; n, number of mice. BrdU 
staining of PDAC tissue samples 
from Kras p16 and Kras RelA p16 
mice. Scale bar: 100 μm. The number 
of BrdU-positive cells was counted 
per tumor area. Mean ± SD; n = 4; 
**P = 0.0012 by unpaired t test; 
n, number of mice. (C) Schematic 
illustrating the dual role of RelA in 
pancreatic carcinogenesis. In early 
stages of tumorigenesis, the tumor-
suppressive function of NF-κB is 
beneficial because it controls OIS by 
regulating the CXCL1/CXCR2 axis. 
However, as soon as OIS is bypassed 
during late stages of tumorigenesis, 
NF-κB supports tumor progression.
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pancreata. Treatment of these cells with a specific NF-κB inhibitor 
(JSH-23) was accompanied by decreased SA-β-Gal activity (Figure 
5A and Supplemental Figure 7A). JSH-23 has been demonstrated 
to block nuclear translocation and transcription activity of RelA 
(22). Given the documented effect of NF-κB on the expression of 
immune mediators (11), we used antibody arrays to monitor the 
expression profile of secreted cytokines and chemokines in condi-
tioned media from PDEC Kras and PDEC Kras treated with JSH-23. 
As expected, inhibition of nuclear translocation and transcription-
al activity of RelA specifically decreased the expression of certain 
inflammatory mediators, including G-CSF, GM-CSF, sICAM-1, 
CCl-5, TIMP-1, and TNF-α (Figure 5, B and C). Of the 40 cytokines 
and chemokines represented in this panel, CXCL1 (also known as 
KC) was most robustly downregulated in PDEC Kras treated with 
JSH-23 (Figure 5, B and C). The decrease in CXCL1 protein lev-
els was corroborated by an increased SA-β-Gal activity in PDEC 
Kras incubated with CXCL1 for 48 hours (Figure 5D). Next, we 
investigated the involvement of CXCL1 in vivo by determining the 
cellular localization of Cxcl1 mRNA expression in pancreata from 
13-week-old Kras and Kras RelA mice using the RNAscope meth-
od for in situ mRNA detection. In Kras pancreata, Cxcl1 mRNA 
expression was moderately to strongly present in the cytoplasm of 
most duct cells in mPanIN lesions, in acinar cells around mPanIN 
lesions, and in immune cells. Interestingly, Cxcl1 mRNA was pres-
ent in immune cells, only faintly present in a few duct cells, and 
absent in the majority of acinar cells in Kras RelA pancreata (Figure 
5E). To determine the relevance of the observed link between the 
activation of RelA and CXCL1-dependent OIS, we used transgen-
ic mice expressing IL8, the human orthologue of murine CXCL1 
[Tg(IL8), hereafter referred to as IL-8tg]. IL-8tg mice carry a bac-
terial artificial chromosome that encompasses the entire human 
IL8 gene, including its regulatory elements (23). This mouse 
line was crossed to the Kras RelA strain to obtain LSL-KrasG12D 
Relafl/fl IL-8Tg Ptf1a-Creex1 mice (hereafter referred to as Kras RelA 
IL-8tg mice). Analysis and quantification of SA-β-Gal activity dem-
onstrated a significantly higher percentage of SA-β-Gal–positive 
cells in low-grade lesions arising from Kras RelA IL-8tg pancreata 
compared with Kras RelA animals (Figure 5, F and G). Notably, 
IL-8 per se was sufficient to increase the number of SA-β-Gal–posi-
tive cells in low-grade mPanIN and to impede mPanIN progres-
sion in Kras animals (Supplemental Figure 7, B–D). But most strik-
ingly, the phenotype of accelerated progression of mPanIN lesions 
in Kras RelA mice was nearly totally abrogated in the context of 
IL-8 expression (Figure 5, H and I). Coinciding with reinforce-
ment of OIS and blocked mPanIN progression, induction of p53 in 
mPanIN was strongly detectable (Figure 5J). In line with the anti-
oxidative function of p53, accumulation of ROS in mPanIN lacking 
RelA was also diminished in Kras RelA IL-8tg mice (Figure 5J).
Thus, these results strongly support the notion that CXCL1 
contributes to the regulation of OIS via RelA activation in vivo 
and in vitro.
Systemic pharmacological and genetic inactivation of CXCR2 
abrogates OIS and accelerates pancreatic carcinogenesis. Since 
CXCL1 acts through the chemokine receptor CXCR2, which is 
strictly expressed in PanIN lesions, but not in normal ductal epi-
thelium, we then investigated whether CXCR2 is instrumental 
for reinforcement of OIS (Figure 6A). To this end, we treated 
analyzed a panel of senescence-associated markers in pancreata 
from Kras and Kras RelA mice. The most commonly used bio-
marker of OIS in vivo is an elevated activity of senescence-asso-
ciated β-galactosidase (SA-β-Gal), derived from the acidic lyso-
somal β-galactosidase (12). Quantification of SA-β-Gal–positive 
cells in low-grade mPanIN lesions from Kras and Kras RelA mice 
demonstrated loss of SA-β-Gal activity in Kras RelA mPanIN (Fig-
ure 4, A and B). In addition, the senescence marker decoy recep-
tor 2 (DCR2; also known as TNFRSF10D) was significantly lower 
in Kras RelA pancreata than in Kras pancreata on both an mRNA 
expression and a protein level (Figure 4, C–E, and Supplemental 
Figure 5). Along the same lines, p53 and p21 mRNA and associ-
ated protein levels were downregulated in isolated pancreata 
of Kras RelA mice compared with Kras mice (Figure 4, C–E, and 
Supplemental Figure 5); mRNA levels of basic helix–loop–helix 
transcription factor BHLHE40 (also known as dec1) also tend to 
be lower in Kras RelA mice (Figure 4C). Moreover, Western blot 
and immunohistological examinations revealed the downregula-
tion of p16 and p19 in Kras RelA pancreata (Figure 4, D and E, and 
Supplemental Figure 5).
Recent studies have established that senescent cells secrete 
inflammatory cytokines and chemokines, extracellular proteases, 
and growth factors, collectively subsumed as the senescence-
associated secretory phenotype (SASP). These factors are not 
only known to be NF-κB targets, but are also required to reinforce 
OIS. GSEA demonstrated a loss of the SASP signature in Kras RelA 
mice (Figure 4F).
Further, SASP is known to contribute to the surveillance 
and elimination of senescent cells through a tumor-suppressive 
immune response during the early stages of tumorigenesis (20, 
21). To characterize the immune response in Kras and Kras RelA 
mice during pancreatic carcinogenesis, we digested the pancre-
ata of 8-week-old mice and performed FACS analyses. In Kras 
RelA pancreata total macrophage population was significantly 
increased as shown by FACS using general macrophage markers 
(CD11b+F4/80+) (Supplemental Figure 6, A and B) and IHC (Sup-
plemental Figure 6C). Among the total macrophage population, 
myeloid-derived suppressor cells (MDSCs; CD11b+Gr-1+), typi-
cally abundant within the pancreatic cancer microenvironment 
and implicated in immunosuppression, were more prominently 
found in neoplastic pancreata of Kras RelA than in Kras mice 
(Supplemental Figure 6D). FACS analysis further demonstrated 
an enrichment of macrophages expressing the additional M2 
marker CD206 (CD206+CD11b+F4/80+) in Kras RelA pancreata, 
indicative of an M2 polarization (Supplemental Figure 6, E and 
F). Furthermore, deletion of Rela in the pancreas of Kras mice led 
to decreased expression of genes associated with M1 activation, 
namely Ifng, Tnf, Il12b, Cox2, and Il23a (Supplemental Figure 6G).
Thus, our data indicate that RelA activation is required to 
reinforce OIS in mPanIN cells, which also impacts immune 
response. Deletion of Rela in neoplastic Kras pancreata supports 
a protumorigenic microenvironment. Subsets of protumorigenic 
M2 macrophages and MDSCs were found to be increased in the 
stroma of Kras RelA mice.
Activation of RelA-dependent signaling promotes OIS through 
CXCL1. Since OIS is induced in early mPanIN lesions, we isolated 
primary pancreatic duct epithelial cells (PDEC Kras) from Kras 
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during pancreatic carcinogenesis in a mouse model. Our data fur-
ther provide evidence for the importance of the CXCL1/CXCR2 
axis for pancreatic tumorigenesis in humans alike.
Reinforcement of OIS determines the dual role of RelA during 
pancreatic carcinogenesis. So far, our data indicate the significance 
of RelA in CXCL1/CXCR2-dependent OIS and its role as a tumor 
suppressor during the early stages of pancreatic tumorigenesis. To 
further genetically corroborate the implication of RelA in this nov-
el and early mechanism of tumor surveillance, we took advantage 
of murine PDAC models that progress to pancreatic cancer via 
bypassing OIS. Since functional studies have demonstrated that 
senescence requires the p53 and p16/Rb pathways (25, 26), and 
their abrogation is necessary to bypass senescence, we crossed 
floxed RelA mice to Kras mice that lacked p53 or p16 in the pancre-
as (16). All mice progressed to PDACs. As expected, in the absence 
of OIS (data not shown), survival analysis demonstrated that sur-
vival of LSL-KrasG12D Relafl/fl Trp53fl/fl Ptf1a-Creex1 (termed Kras RelA 
Trp53) and LSL-KrasG12D Relafl/fl Ink4afl/fl Ptf1a-Creex1 (termed Kras 
RelA p16) mice was significantly longer in comparison with LSL-
KrasG12D Trp53fl/fl Ptf1a-Creex1 (termed Kras Trp53) and LSL-KrasG12D 
Ink4afl/fl Ptf1a-Creex1 (termed Kras p16), respectively (Figure 8, A and 
B). Established tumors in these mice revealed decreased prolifera-
tion after functional inactivation of RelA (Figure 8, A and B).
Taken together, these data clearly demonstrate a dual role 
of NF-κB/RelA activation in pancreatic carcinogenesis. In early 
stages of tumorigenesis, the tumor-suppressive function of NF-κB 
is beneficial because it controls OIS by regulating the CXCL1/
CXCR2 axis (Figure 8C). However, as soon as OIS is bypassed 
during late stages of tumorigenesis, NF-κB supports tumor pro-
gression by enhancing proliferation of the transformed pancreatic 
cancer cells (Figure 8C).
Discussion
Our results illustrate several mechanisms that reveal the complex-
ity of the IKK/NF-κB pathway during pancreatic carcinogenesis. 
Furthermore, they highlight several new aspects that need to be 
considered, especially when exploring the use of specific IKK/
NF-κB and CXCR2 inhibitors as chemotherapeutic agents.
Recent studies have demonstrated that the components of the 
IKK complex IKK2 and NEMO drive progression of premalignant 
lesions to PDAC (1–3). However, because these kinase subunits 
have pleiotropic effects, it has remained unclear whether tumor 
promotion is directly mediated by the IKK/NF-κB pathway (10). 
Some studies have confirmed the tumor-enhancing function of 
the NF-κB subunit RelA in a mouse model of pulmonary adenocar-
cinoma (4). However, to date, no study has implicated RelA activa-
tion in spontaneous tumor formation in vivo in the pancreas. Using 
an in vivo model of pancreatic cancer, we investigated the function 
of RelA in the KrasG12D mouse line. Surprisingly, in contrast to IKK2 
or NEMO, we noted rapid initiation and progression of preneo-
plastic lesions along with PDAC development in RelA-deficient 
KrasG12D mice, revealing a tumor-suppressive function for RelA. 
In contrast to the IKK complex, RelA is directly and immediately 
transferring cytoplasmic signals to the nucleus through binding of 
DNA, thus controlling transcription. However, blocked pancreatic 
carcinogenesis in IKK2/NEMO-deficient KrasG12D mice was not 
mediated directly by the NF-κB pathway, but through interlinked 
PDEC Kras with CXCL1 or with a combination of CXCL1 and a 
CXCR2 antagonist (SB225002) in vitro. The results demonstrated 
increased SA-β-Gal activity in PDEC Kras treated with CXCL1, but 
decreased SA-β-Gal activity in PDEC Kras treated with a combina-
tion CXCL1 and SB225002 (Figure 6B). To examine the relevance 
of the CXCR2 receptor in vivo, we treated 5-week-old Kras mice 
with SB225002 according to the protocol shown in Figure 6C or 
crossed LSL-KrasG12D Pdx1-Cre mice (referred to as *Kras mice) 
to the Cxcr2–/– mouse line (LSL-KrasG12D Pdx1-Cre Cxcr2–/– mice, 
referred to hereafter as *Kras Cxcr2null). The Cxcr2–/– mouse 
line lacks the receptor in the whole organism. We observed a 
dramatically decreased SA-β-Gal activity in low-grade mPanIN 
of the SB225002-treated group (Figure 6D) alongside acceler-
ated tumorigenesis (Figure 6E). Similarly, *Kras Cxcr2null mice 
revealed accelerated mPanIN progression; even some focal can-
cers developed in 18-week-old mice, which is normally not seen in 
*Kras mice at this age (Figure 6, F and G).
Thus, our data suggest that either pharmacological or genetic 
systemic inactivation of CXCR2 leads to prevention of OIS, which 
in turn leads to accelerated pancreatic carcinogenesis.
Pancreas-specific inactivation of CXCR2 is sufficient to prevent 
OIS. To further corroborate the relevance of mPanIN-restricted 
CXCR2 for OIS in preneoplastic lesions we generated an addition-
al *Kras mouse line, lacking CXCR2 in the pancreas. To this end, 
*Kras mice were crossed to floxed Cxcr2 mice to obtain the LSL-
KrasG12D Cxcr2fl/fl Pdx1-Cre line (referred to as *Kras Cxcr2 mice). 
Loss of CXCR2 in the pancreas resulted in impaired OIS and sub-
sequently in increased proliferation (Figure 7A and Supplemental 
Figure 8, A and B). Histologically, mPanIN progression in *Kras 
Cxcr2 mice was accelerated (Supplemental Figure 8C). Notably, 
some *Kras Cxcr2 mice developed focal cancers similar to those 
in *Kras mice lacking systemic CXCR2 expression. These obser-
vations were paralleled by decreased survival of *Kras mice lack-
ing CXCR2 either in mPanIN lesions (green line) or in the whole 
organism (blue line) (Figure 7B). To determine the relevance of 
the CXCL1/CXCR2 axis for the human disease, we stained human 
pancreatic cancer specimens for CXCR2 (Figure 7C). Similarly 
to our observations in mice, expression of CXCR2 was detect-
able in low-grade, but lost in high-grade, human PanIN (hPanIN) 
lesions. Transcript analysis of microdissected low-grade hPanIN 
lesions and human pancreatic cancer cells revealed significantly 
increased expression levels of Cxcl1, Cxcl2, and Cxcl6 in low-grade 
hPanIN compared with human PDAC specimens (Figure 7D).
Moreover, we also investigated the expression of CXCR2 
together with Ki-67, p53, and p16 in human normal pancreatic ducts 
as well as low-grade (hPanIN-1/2) and high-grade (hPanIN-3) 
hPanIN lesions by IHC. Supplemental Figure 8D demonstrates 
that CXCR2 and p16 decline as hPanIN lesions progress. In accor-
dance with the induction of senescence in low-grade lesions, 
proliferation of these ducts is reduced (Supplemental Figure 8D). 
Conversely, p53 overexpression, which serves as a marker for the 
presence of p53 mutations, occurs only in high-grade hPanIN-3 
lesions but is absent in low-grade hPanIN lesions (Supplemental 
Figure 8D), suggesting that expression of CXCR2 shares similari-
ties with markers of OIS in human premalignant lesions (24).
These experiments demonstrate a direct impact of CXCR2 in 
ductal cells in the reinforcement of OIS in preneoplastic lesions 
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recruitment of MDSCs was shown to depend on CXCL1/CXCR2. 
Recent work identifies CXCR2 as a new target for therapies 
aimed at inhibiting MDSC recruitment, providing a rationale for 
combining immune checkpoint inhibitors with agents designed to 
prevent MDSC-mediated immune suppression for cancer therapy 
(43). However, it seems that this mechanism is not crucial for the 
recruitment of MDSCs in the absence of OIS during Kras-induced 
pancreatic carcinogenesis. Beyond the CXCR2 ligands in mice 
(CXCL1, CXCL2/3, CXCL5, and CXCL7), several other factors, 
such as S100A8/A9, have been shown to attract myeloid cells 
to the tumor microenvironment (44). These factors do not only 
induce the accumulation of MDSCs; they are also secreted by 
MDSCs and by tumor cells to ensure the maintenance of func-
tionally suppressive MDSCs within a tumor environment. Thus, 
rather than promoting inflammation, activation of RelA regulates 
the fine-tuning of tumor-inhibitory and tumor-promoting effects 
via SASP immune responses.
Of all SASP components, the CXCR2 ligand CXCL1 was 
shown to be required for OIS induction in vitro, whereas others, 
including IL-6 and IL-1β, have been shown to promote malignant 
phenotypes (45–47). Consistent with a previous study, PDECs 
that expressed KrasG12D failed to undergo senescence without 
incubation with CXCL1 (15). CXCR2 in the pancreas of Kras 
mice is restricted to ductal cells. Although most studies have 
endorsed a pro-oncogenic function of CXCL1 and the human 
ortholog IL-8 in human tumors (48), our pharmacological and 
genetic approaches suggest a tumor surveillance role in pancre-
atic oncogenesis through the RelA-dependent regulation of the 
IL-8/CXCL1/CXCR2 axis. The CXCL1/CXCR2 axis is a critical 
regulatory system that reinforces growth arrest through senes-
cence in vitro. Importantly, genetic and pharmaceutical block-
age of CXCR2 in vivo mimicked a RelA-deficient phenotype, 
with reduced senescence and increased mPanIN progression. In 
contrast, overexpression of the human ortholog of IL-8 inhibited 
progression of preneoplastic lesions through expansion of senes-
cent mPanIN lesions (25). However, the effects of CXCR2 on 
pancreatic oncogenesis appear to be context- and stage-depen-
dent, because a recent study has demonstrated that CXCR2 
promotes the development of PDAC in a mouse model (49). 
Notably, in this study activation of KrasG12D was achieved by the 
Pdx1-Cre mouse line. Further, in the context of chronic inflam-
mation–induced carcinogenesis in the colon, loss of CXCR2 sup-
presses inflammation-associated tumorigenesis. These effects 
have been attributed to the inhibition of infiltration of MDSCs 
into the colonic mucosa. However, in the context of spontaneous 
Kras-driven cancer development, CXCR2 and its ligands seem to 
play a central role in establishing OIS. Once OIS has been over-
come, CXCR2 signaling seems to switch from a tumor suppres-
sor to a tumor promoter (50).
In summary, we have examined the in vivo function of RelA 
during pancreatic oncogenesis, which comprises a dual mecha-
nism (51–54). While on the one hand RelA inhibits the develop-
ment of preneoplastic lesions by reinforcing senescence through 
the CXCL1/CXCR2 axis, its activation in established tumors 
promotes the cancer cell proliferation. Examining these context-
dependent activities of RelA will be important for effective clinical 
use of NF-κB inhibitors. Furthermore, these findings underscore 
pathways such as Notch, KLF, or IL-1/p62 (1–3). In fact, the IKK 
complex provides a basis for manifold cross-talk with other signal-
ing pathways, as well as feedback circuits. In contrast to Kras RelA 
mice, comparative analysis of gene signatures revealed significant 
differences, including upregulation of numerous nonoverlapping 
pathways, in Pdx1-Cre LSL-KrasG12D IKK2fl/fl mice (Supplemental 
Table 1, A and B) (1). Loss of IKK2 resulted in induction of several 
pathways, mainly related to metabolism and biosynthesis, where-
as functional inactivation of RelA only promoted cell stress and 
cell differentiation pathways. This further underlines substantial 
differences between the components of the IKK/NF-κB pathway. 
Although most studies have demonstrated a pro-oncogenic func-
tion of NF-κB, our findings are consistent with a tumor-suppres-
sive function, as observed in other tumor models of the skin, the 
liver, and lymphomas (7, 9, 27, 28).
OIS is a failsafe mechanism that prevents the development of 
cancer in precancerous lesions of various tumors, including PDAC 
(29). Malignant cells are unable to undergo senescence, because 
of the loss of OIS effectors, such as p53 or p16 (30). The molecu-
lar mechanisms that regulate OIS during pancreatic oncogenesis 
are unknown. Using various mouse models of pancreatic cancer, 
we have provided novel findings that show that OIS requires acti-
vation of the RelA-dependent canonical NF-κB pathway during 
mPanIN progression. Senescence is mediated by cell-autonomous 
and non–cell-autonomous mechanisms that regulate OIS in a 
paracrine manner. Preneoplastic ductal cells that express KrasG12D 
are not only the chief source of SASP components; mPanIN lesions 
are also the recipients, undergoing OIS through CXCR2 activa-
tion. The SASP comprises cytokines, chemokines, matrix metal-
loproteinases, and other proteins, most of which are regulated 
by NF-κB (11, 31–35). SASP components, such as IL-1β, IL-6, and 
CXCL1, were less prominently induced in Kras mice lacking RelA 
in the pancreas. Consequently, OIS was attenuated in these mice, 
whereas mice expressing KrasG12D since embryonic development 
showed increased SA-β-Gal activity and widespread OIS in most 
early preneoplastic lesions (12). Our findings support the notion 
that induction of OIS in Kras mice necessitates the activation of 
RelA to regulate SASP (11, 29). RelA has been shown to cooper-
ate with p53 in the execution of the senescence program (36). This 
interplay influences macrophage polarization and the subsequent 
targeting of senescent cells.
RelA also showed a potent effect on macrophage regulation. 
Tumor-associated macrophages can be polarized toward a clas-
sical, proinflammatory phenotype M1, or toward an alternative, 
anti-inflammatory M2 response. M1 macrophages are character-
ized by a proinflammatory cytokine profile and are potent kill-
ers of tumor cells, while M2 macrophages show mainly tumor-
enhancing functions, promoting cell survival and proliferation 
(37, 38, 39). Interestingly, the senescent state triggered by KrasG12D 
caused a significant increase in the secretion of factors known to 
promote M1 polarization, which is characterized by an increased 
propensity for cell killing and phagocytosis (40). Loss of RelA was 
associated with suppression of secretion of these factors and pro-
motion with M2 polarization of macrophages and accumulation 
of MDSCs. MDSCs have been implicated in promoting tumor 
growth by suppressing antitumor immunity (41, 42). Interest-
ingly, in the context of inflammation-associated tumorigenesis, 
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then passed through a Corning 70-μm Cell Strainer (catalog 352350; 
Corning). Spleens were crushed, passed through a 70-μm cell strain-
er, washed once with PBS/2% FCS, and treated with rbc lysis buffer 
(catalog R7757; Sigma-Aldrich) for 90 seconds to eliminate rbcs. Cell 
suspensions were stained in PBS/2% FCS with the following anti-
bodies: CD45 (clone 30-F11), CD3e (clone 145-2C11), CD11b (clone 
M1/70), F4/80 (clone BM8; all from eBioscience); CD206 (clone 
C068C2), CD4 (clone GK1.5) (all from BioLegend); and Gr-1 (clone 
RB6-8C5) (Thermo Fisher Scientific). Flow cytometry analysis was 
performed using a Gallios flow cytometer (Beckman Coulter) after 
gating and exclusion of dead cells. Data were analyzed using a soft-
ware package (FlowJo).
Accession number. Microarray data are available in the ArrayEx-
press database (www.ebi.ac.uk/arrayexpress) under accession num-
ber E-MTAB-3436.
Supplemental Methods. For all methods not listed here, please refer 
to the online Supplemental Methods section.
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that caution should be exercised when exploring the use of phar-
maceuticals targeting the CXCR2 receptor as a therapeutic option 
for the treatment of various solid tumors.
Methods
Mice. LSL-KrasG12D knock-in, Ptf1a-Creex1, RelAfl/fl (termed RelAwt), 
Trp53fl/fl, Ink4a, and Tg(IL8) strains were interbred to obtain the com-
pound mutant strains Relafl/fl Ptf1a-Creex1 (termed RelA), LSL-KrasG12D 
RelAfl/fl Ptf1a-Creex1 (termed Kras RelA), LSL-KrasG12D Tg(IL8) Ptf1a-Creex1 
(termed Kras IL-8tg), LSL-KrasG12D Relafl/fl IL-8tg Ptf1a-Creex1 (termed 
Kras RelA IL-8tg), LSL-KrasG12D Trp53fl/fl Ptf1a-Creex1 (termed Kras 
Trp53), LSL-KrasG12D Relafl/fl Trp53fl/fl Ptf1a-Creex1 (termed Kras RelA 
Trp53), LSL-KrasG12D Ink4afl/fl Ptf1a-Creex1 (termed Kras p16), and LSL-
KrasG12D RelAfl/fl Ink4afl/fl Ptf1a-creex1 (termed Kras RelA p16). Mutant 
LSL-KrasG12D Ptf1a-Creex1 mice (termed Kras, the positive control) were 
used as control animals (19, 25, 55–58). LSL-KrasG12D Pdx1-Cre (termed 
*Kras), LSL-KrasG12D Cxcr2fl/fl Pdx1-Cre (termed *Kras Cxcr2), and LSL-
KrasG12D Pdx1-Cre Cxcr2–/– (termed *Kras Cxcr2null) mice were obtained 
from Owen J. Sansom.
RNAscope method for in situ mRNA detection. In situ detection 
of Cxcl1 transcripts in formalin-fixed paraffin-embedded (FFPE) 
pancreatic samples was performed using the RNAscope method 
(Advanced Cell Diagnostics) according to the manufacturer’s instruc-
tions. Briefly, 4-μm FFPE pancreatic sections were pretreated with 
heat, deparaffinized, boiled with a pretreatment solution for 15 min-
utes, and submitted to protease digestion followed by hybridization 
for 2 hours with a target probe for CXCL1. Thereafter, an HRP-based 
signal amplification system was hybridized to the target probe before 
color development with 3,3′-diaminobenzidine tetrahydrochloride. 
Positive staining was defined as the presence of brown dots.The 
housekeeping gene ubiquitin C (Ubc) served as a positive control. 
The DapB gene, which is derived from a bacterial gene sequence, was 
used as a negative control.
Fluorescence-activated cell sorting (FACS). Single-cell suspen-
sions were prepared from fresh pancreas and spleen. Pancreata were 
minced, incubated with 1.2 mg/ml collagenase type VIII (catalog 
C2139; Sigma-Aldrich) and 0.1 mg/ml soybean trypsin inhibitor 
(catalog T9003; Sigma-Aldrich) in PBS for 10 minutes at 37°C, and 
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